Puma Biotechnology, Inc. (PBYI) Stock

Puma Biotechnology, Inc., headquartered in Los Angeles, California, is a leading biopharmaceutical company dedicated to advancing cancer care both domestically and globally. Founded in 2010, Puma Biotechnology focuses on the development and commercialization of innovative therapies aimed at addressing unmet medical needs in oncology. Central to its portfolio are drug candidates like PB272 neratinib, an oral treatment designed for patients with early-stage HER2-overexpressed/amplified breast cancer. Additionally, PB272 is being evaluated in combination with capecitabine for the treatment of advanced or metastatic HER2-positive breast cancer, as well as for HER2 mutation-positive solid tumors.

Puma Biotechnology's strategic alliances play a crucial role in its mission to bring cutting-edge treatments to patients worldwide. The company has established significant license agreements with Pfizer, Inc. and sub-license agreements with leading global entities such as Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, and Knight Therapeutics, Inc., among others. These partnerships underscore Puma Biotechnology's commitment to expanding access to its innovative therapies and advancing cancer treatment options.

With a strong emphasis on research and development, Puma Biotechnology continues to drive progress in oncology through rigorous clinical trials and regulatory initiatives. By leveraging its expertise and strategic collaborations, the company aims to improve outcomes and quality of life for patients facing challenging forms of cancer, reinforcing its position as a key player in the biopharmaceutical industry.